Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

Trial Profile

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Prednisolone; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PROSELICA
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Oct 2016 Results of post-hoc analyses assessing the association of grade 3-4 neutropenia on treatment and baseline neutrophil-lymphocyte ratio with overall survival presented at the 41st European Society for Medical Oncology Congress.
    • 07 Jun 2016 Results of 2 phase III trials (FIRSTANA, n=315 and PROSELICA, n=256) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top